Aktis Oncology, Inc. AKTS
14.94 USD +0.35 (+2.40%)
At closeNov 3, 2026, 4:00 PM EST
14.90 -0.04 -0.27%
After hours · Nov 3, 4:00 PM ET
14.40 Day range 15.09
13.96 52-week range 34.19
- YTD
- -33.30%
- 1 year
- -33.30%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 35.39 +136.9% upside
Now 14.94
- Target (low)
- 31.50
- Target (mean)
- 35.39
- Target (high)
- 40.00
Ratings (0m) 10 10 buy · 0 hold · 0 sell
- Strong buy1
- Buy9
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 10
- 1 month ago 10
- 2 months ago 9
- 3 months ago 7
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.45803 | -0.56 – -0.34 | 0.00 | 0.0% | 2.33M | 0.0% | 7 |
| Next quarter | -0.47987 | -0.61 – -0.12 | 0.00 | 0.0% | 2.13M | +13.8% | 7 |
| Current year | -1.69 | -1.95 – -1.27 | -78.34 | +97.9% | 10.25M | +57.7% | 8 |
| Next year | -2.15 | -3.02 – -1.08 | -1.69 | -27.4% | 9.67M | -5.7% | 8 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 2, 2026 | Wedbush | Reiterated | Outperform | Outperform |
| Sep 9, 2026 | Oppenheimer | Initiated | — | Outperform |
| Aug 19, 2026 | Wedbush | Initiated | — | Outperform |
| Aug 19, 2026 | BMO Capital | Initiated | — | Outperform |
| Jul 14, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Jun 16, 2026 | Raymond James | Initiated | — | Strong Buy |
| Jun 2, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Apr 29, 2026 | William Blair | Initiated | — | Outperform |
| Mar 31, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Mar 9, 2026 | HC Wainwright & Co. | Initiated | — | Buy |
| Feb 3, 2026 | Leerink Partners | Initiated | — | Outperform |
| Feb 3, 2026 | JP Morgan | Initiated | — | Overweight |
| Jan 4, 2024 | Piper Sandler | Downgrade | Overweight | Neutral |
| Sep 7, 2023 | Oppenheimer | Maintained | Outperform | Outperform |
| Sep 7, 2023 | B. Riley Securities | Downgrade | Buy | Neutral |
| May 9, 2023 | Oppenheimer | Maintained | — | Outperform |
| May 9, 2023 | Roth MKM | Maintained | — | Buy |
| Jan 24, 2023 | B. Riley Securities | Initiated | — | Buy |
| Nov 15, 2022 | Oppenheimer | Maintained | — | Outperform |
| Sep 13, 2022 | Piper Sandler | Maintained | — | Overweight |
| May 3, 2022 | Piper Sandler | Maintained | — | Overweight |
| Nov 2, 2021 | Oppenheimer | Maintained | — | Outperform |
| May 4, 2021 | Roth Capital | Maintained | — | Buy |
| Jan 4, 2021 | Roth Capital | Maintained | — | Buy |
| Dec 20, 2019 | Northland Capital Markets | Maintained | — | Market Perform |
| Sep 18, 2019 | Northland Capital Markets | Downgrade | Outperform | Market Perform |
| Jul 10, 2019 | Northland Capital Markets | Upgrade | Market Perform | Outperform |
| Feb 5, 2019 | Northland Capital Markets | Downgrade | Outperform | Market Perform |
| Aug 30, 2018 | Oppenheimer | Initiated | — | Outperform |
| Jun 22, 2018 | Loop Capital | Initiated | — | Buy |